Overview

Enzalutamide for Bladder Cancer Chemoprevention

Status:
Terminated

Trial end date:
2018-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine the effect of androgen deprivation therapy through administration of enzalutamide on preventing bladder cancer recurrences in patients with non-muscle invasive bladder cancer (NMIBC).

Phase:

Phase 2

Details

Lead Sponsor:

University of Rochester

Collaborator:

Astellas Pharma Inc

Treatments:

Androgens